Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma

被引：0
|
作者：
Chapman, P. B.
Hauschild, A.
Robert, C.
Larkin, J. M. G.
Haanen, J. B. A. G.
Ribas, A.
Hogg, D.
O'Day, S.
Ascierto, P. A.
Testori, A.
Lorigan, P.
Dummer, R.
Sosman, J. A.
Garbe, C.
Lee, R. J.
Nolop, K. B.
Nelson, B.
Hou, J.
Flaherty, K. T.
McArthur, G. A.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Klinikum Schleswig Holstein, Kiel Schleswig Holstein, Germany
[3] Canc Inst Gustave Roussy, Villejuif, France
[4] Royal Marsden Hosp, Urol Unit, London SW3 6JJ, England
[5] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[6] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[7] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[8] Univ Toronto, Toronto, ON, Canada
[9] Angeles Clin & Res Inst, Los Angeles, CA USA
[10] Ist Nazl Tumori, Naples, Italy
[11] European Inst Oncol, Milan, Italy
[12] Christie Hosp, Manchester, Lancs, England
[13] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[15] Univ Tubingen, Tubingen, Germany
[16] Hoffmann La Roche Inc, Pharma Res & Early Dev, Nutley, NJ 07110 USA
[17] Plexxikon Inc, Berkeley, CA USA
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Massachusetts Gen Hosp, Boston, MA 02114 USA
[20] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas
    Chapman, P. B.
    Hauschild, A.
    Robert, C.
    Larkin, J. M. G.
    Haanen, J. B. A. G.
    Ribas, A.
    Hogg, D.
    O'Day, S.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P.
    Dummer, R.
    Sosman, J. A.
    Garbe, C.
    Lee, R. J.
    Nolop, K. B.
    Nelson, B.
    Hou, J.
    Flaherty, K. T.
    McArthur, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Larkin, James M. G.
    Haanen, John B. A. G.
    Ribas, Antoni
    Hogg, David
    Hamid, Omid
    Ascierto, Paolo Antonio
    Testori, Alessandro
    Lorigan, Paul
    Dummer, Reinhard
    Sosman, Jeffrey Alan
    Garbe, Claus
    Maio, Michele
    Nolop, Keith B.
    Nelson, Betty J.
    Joe, Andrew K.
    Flaherty, Keith T.
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase III, randomized, open-label, multicenter trial (BREAK3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
    Hauschild, Axel
    Grob, Jean Jacques
    Demidov, Lev V.
    Jouary, Thomas
    Gutzmer, Ralf
    Millward, Michael
    Rutkowski, Piotr
    Blank, Christian U.
    Mirakhur, Beloo
    Guckert, Mary E.
    Swann, R. Suzanne
    Haney, Patricia
    Martin, Anne-Marie
    Ouellet, Danielle
    Grotzinger, Kelly
    Goodman, Vicki L.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
    Ribas, A.
    Kim, K. B.
    Schuchter, L. M.
    Gonzalez, R.
    Pavlick, A. C.
    Weber, J. S.
    McArthur, G. A.
    Hutson, T. E.
    Flaherty, K. T.
    Moschos, S. J.
    Lawrence, D. P.
    Hersey, P.
    Kefford, R. F.
    Chmielowski, B.
    Puzanov, I.
    Li, J.
    Nolop, K. B.
    Lee, R. J.
    Joe, A. K.
    Sosman, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
    Dummer, Reinhard
    Flaherty, Keith T.
    Robert, Caroline
    Arance, Ana
    de Groot, Jan Willem B.
    Garbe, Claus
    Gogas, Helen J.
    Gutzmer, Ralf
    Krajsova, Ivana
    Liszkay, Gabriella
    Loquai, Carmen
    Mandala, Mario
    Schadendorf, Dirk
    Yamazaki, Naoya
    di Pietro, Alessandra
    Cantey-Kiser, Jean
    Edwards, Michelle
    Ascierto, Paolo A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +
  • [6] An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)
    Hauschild, Axel
    Grob, Jean Jacques
    Demidov, Lev V.
    Jouary, Thomas
    Gutzmer, Ralf
    Millward, Michael
    Rutkowski, Piotr
    Blank, Christian U.
    Miller, Wilson H.
    Kaempgen, Eckhart
    Martin-Algarra, Salvador
    Karaszewska, Boguslawa
    Mauch, Cornelia
    Chiarion-Sileni, Vanna
    Mirakhur, Beloo
    Guckert, Mary E.
    Swann, R. Suzanne
    Haney, Patricia
    Goodman, Vicki L.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Vemurafenib Improves Overall Survival Compared to Dacarbazine in Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multicentre Trial
    McArthur, G.
    Hauschild, A.
    Robert, C.
    Haanen, J. B.
    Ascierto, P.
    Lee, R. J.
    Nolop, K.
    Nelson, B.
    Flaherty, K. T.
    Chapman, P. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 14 - 14
  • [8] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
    Schadendorf, Dirk
    Dummer, Reinhard
    Flaherty, Keith T.
    Robert, Caroline
    Arance, Ana
    de Groot, Jan Willem B.
    Garbe, Claus
    Gogas, Helen J.
    Gutzmer, Ralf
    Krajsova, Ivana
    Liszkay, Gabriella
    Loquai, Carmen
    Mandala, Mario
    Yamazaki, Naoya
    Queirolo, Paola
    Guenzel, Carolin
    Polli, Anna
    Thakur, Mahgull
    di Pietro, Alessandra
    Ascierto, Paolo A.
    EUROPEAN JOURNAL OF CANCER, 2024, 204
  • [9] BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma
    Chisholm, Julia C.
    Suvada, Jozef
    Dunkel, Ira J.
    Casanova, Michela
    Zhang, Weijiang
    Ritchie, Natasha
    Choi, YounJeong
    Park, Jane
    Das Thakur, Meghna
    Simko, Stephen
    Tam, Nga Wan Rachel
    Ferrari, Andrea
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [10] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
    Grippo, J. F.
    Zhang, W.
    Heinzmann, D.
    Yang, K. H.
    Wong, J.
    Joe, A. K.
    Munster, P.
    Sarapa, N.
    Daud, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 103 - 111
12345